 2021 Earnings Call Summary for Labcorp

In the third quarter of 2021, Labcorp reported strong results with revenue of $4.1 billion, adjusted earnings per share of $6.82, and free cash flow of $650 million. The company's Diagnostics and Drug Development businesses performed well, with growth of 10% and 22%, respectively. COVID testing volumes were higher than anticipated, with an average of 85,000 tests per day in the quarter. Labcorp continues to support the fight against the pandemic through both its diagnostic and drug development capabilities. The company is also working on bringing new innovations to market, including an FDA-authorized COVID and flu-at-home collection kit and a successful collaboration with AstraZeneca on a COVID prevention and treatment trial. Labcorp is raising full-year guidance for revenue, adjusted earnings per share, and free cash flow based on its strong third-quarter performance and improved outlook.